A Pathway Analysis Based on Genome-Wide DNA Methylation of Chinese Patients with Graves' Orbitopathy.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
07
2018
accepted:
25
12
2018
entrez:
9
2
2019
pubmed:
9
2
2019
medline:
28
5
2019
Statut:
epublish
Résumé
The pathogenesis Graves' Orbitopathy (GO) is not yet fully understood. Here, we conducted a pathway analysis based on genome-wide DNA methylation data of Chinese GO patients to explore GO-related pathways and potential feature genes. Six GO patients and 6 age-matched control individuals were recruited, and a genome-scale screen of DNA methylation was measured using their peripheral blood sample. After extracting the differentially methylated regions (DMRs), we classified DMRs into three clusters with respect to median absolute deviation (MAD) for GO and control group, respectively. Then the extract tests were performed to identify significant pathways by comparing the counts of genes in each cluster between GO and control group in a pathway. For each significant pathway, we calculated the Methylation-based Inference of Regulatory Activity (MIRA) score to infer the regulatory activity of genes involved in the pathway. Furthermore, we took the significant pathways as the subsets and applied Random forests (RF) method to extract GO-related feature genes. We identified four potential significant pathways associated with the occurrence and development of GO disease. There were Toxoplasmosis, Axon guidance, Focal adhesion, and Proteoglycans in cancer (p<0.001 or p=0.007). The identified genes involved in the significant pathways, such as LDLR (p=0.019), CDK5 (p=0.036), and PIK3CB (p=0.020), were found to be correlated with GO phenotype. Our study suggested pathway analyses can help understand the potential relationships between the DNA methylation level of some certain genes and their regulation in Chinese GO patients.
Sections du résumé
BACKGROUND
BACKGROUND
The pathogenesis Graves' Orbitopathy (GO) is not yet fully understood. Here, we conducted a pathway analysis based on genome-wide DNA methylation data of Chinese GO patients to explore GO-related pathways and potential feature genes.
METHODS
METHODS
Six GO patients and 6 age-matched control individuals were recruited, and a genome-scale screen of DNA methylation was measured using their peripheral blood sample. After extracting the differentially methylated regions (DMRs), we classified DMRs into three clusters with respect to median absolute deviation (MAD) for GO and control group, respectively. Then the extract tests were performed to identify significant pathways by comparing the counts of genes in each cluster between GO and control group in a pathway. For each significant pathway, we calculated the Methylation-based Inference of Regulatory Activity (MIRA) score to infer the regulatory activity of genes involved in the pathway. Furthermore, we took the significant pathways as the subsets and applied Random forests (RF) method to extract GO-related feature genes.
RESULTS
RESULTS
We identified four potential significant pathways associated with the occurrence and development of GO disease. There were Toxoplasmosis, Axon guidance, Focal adhesion, and Proteoglycans in cancer (p<0.001 or p=0.007). The identified genes involved in the significant pathways, such as LDLR (p=0.019), CDK5 (p=0.036), and PIK3CB (p=0.020), were found to be correlated with GO phenotype.
CONCLUSION
CONCLUSIONS
Our study suggested pathway analyses can help understand the potential relationships between the DNA methylation level of some certain genes and their regulation in Chinese GO patients.
Identifiants
pubmed: 30733969
doi: 10.1155/2019/9565794
pmc: PMC6348866
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9565794Références
N Engl J Med. 2001 Mar 22;344(12):907-16
pubmed: 11259725
Am J Ophthalmol. 2006 Jul;142(1):147-153
pubmed: 16815265
J Neurochem. 2008 Oct;107(1):265-78
pubmed: 18691386
BMC Bioinformatics. 2011 Feb 15;12 Suppl 1:S10
pubmed: 21342539
Nat Protoc. 2011 Apr;6(4):468-81
pubmed: 21412275
J Thyroid Res. 2012;2012:302537
pubmed: 22175033
J Biol Chem. 2012 May 11;287(20):16917-29
pubmed: 22451679
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2012 Oct 03;13(10):R87
pubmed: 23034086
J Immunol. 2012 Dec 15;189(12):5954-64
pubmed: 23144497
BMC Bioinformatics. 2013;14 Suppl 5:S10
pubmed: 23735126
J Clin Endocrinol Metab. 2014 Jun;99(6):1999-2007
pubmed: 24606088
Invest Ophthalmol Vis Sci. 2014 Mar 20;55(3):1735-48
pubmed: 24651704
BMC Genomics. 2014 Jul 22;15:622
pubmed: 25052024
Chem Biol. 2014 Aug 14;21(8):917-8
pubmed: 25126986
Ophthalmic Res. 2014;52(3):116-23
pubmed: 25248050
PLoS One. 2014 Oct 28;9(10):e110878
pubmed: 25350671
Biochem J. 2016 Feb 15;473(4):397-410
pubmed: 26611753
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
Genomics Proteomics Bioinformatics. 2017 Apr;15(2):101-109
pubmed: 28373027
PeerJ. 2017 May 23;5:e3334
pubmed: 28560097
PLoS One. 2017 Sep 5;12(9):e0184299
pubmed: 28873096
J Endocrinol Invest. 2018 Jun;41(6):719-727
pubmed: 29190000
J Endocrinol Invest. 2018 Jul;41(7):815-820
pubmed: 29256181
Thyroid. 2018 Mar;28(3):386-394
pubmed: 29336220
Bioinformatics. 2018 Aug 1;34(15):2649-2650
pubmed: 29506020